Oncology

Update from ASCO 2022 – Sarcoma

SARCOMA update by Prof. Jonathan Trent, University of Miami Hospital, USA

Prof. Jonathan Trent

Publication Date

Jun 2022

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Prof. Trent discusses the Sarcoma presentation presented at the ASCO 2022 late breaker pleanary session

Phase 3 assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. McCabe M, et al. Abstract LBA2, ASCO 2022

For news on other ASCO 2022 late-breakers covering rectal cancer, breast cancer and multiple myeloma, visit our summary video here

Hi. This is Dr. John Trent here at ASCO to discuss the results of the rEECur trial.

Patients with refractory and relapsed Ewing sarcoma only have less than 15% five-year survival rate.

Treatment is controversial. In this update of the rEECur trial patients were randomised to either topotecan plus Cytoxan (cyclophosphamide) vs high-dose ifosfamide 15 g/m2 (3g/m2 D1-5).

As it turns out, patients who were randomised to topotecan plus Cytoxan (cyclophosphamide) had a 10.5 month median overall survival and a 45% one year survival rate.

On the other hand, those patients randomised to high-dose ifosfamide 15 g/m2 (3g/m2 D1-5) enjoyed a 15.4 month overall survival and a 55% one year survival rate.

All of these benefits from high-dose ifosfamide were statistically significant.

This data is applicable to the standard of care of therapy and is indeed practice changing today. Thank you.

Dr Jonathan C. Trent earned his MD and PhD in cancer biology from The University of Texas Health Science Center where he also completed a residency in internal medicine. He then completed a fellowship in medical oncology at The University of Texas M. D. Anderson Cancer Center while serving as chief fellow. Prior to joining the University of Miami, Sylvester Comprehensive Cancer Center, he held an appointment as associate professor of medicine in the Department of Sarcoma Medical Oncology, Division of Cancer Medicine at the University of Texas M. D. Anderson Cancer Center in Houston. Dr Trent is currently the Associate Director for Clinical Research, the Director of the Bone and Soft-tissue Sarcoma Group and Medical Director of the Precision Medicine Initiative at the Sylvester Comprehensive Cancer Center. Dr Trent’s interests are in the clinical and translational research of sarcomas, direct care of sarcoma patients, and education about sarcoma. As Associate Director for Clinical Research, his goal is to help Sylvester Faculty develop clinical trials that provide clinically effective and scientifically exciting therapy to cancer patients of South Florida and beyond. The major focus of his clinical, educational and research efforts are with gastrointestinal stromal tumor (GIST), chondrosarcoma, and other sarcomas. The major efforts of Dr Trent’s research focus on understanding the mechanisms of action and resistance of imatinib in GIST and other sarcomas while striving toward improved therapeutic options. His work involves the use of novel preoperative/postoperative clinical trials, prospectively acquired tumor tissue, cell lines, archival tissue, as well as collaborations with disciplines such as the genomics facility, surgical oncology, pathology, radiology and interventional radiology.